Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Biosimilar Education Campaign Will Need To Be Targeted

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.


Related Content

Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says
Biosimilar Hearing Will Consider Whether 'Umbrella' Exclusivity Policy Warranted
Biosimilars For US Market May Be Able To Rely On EU-Licensed Reference Products
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Will Epoetin Biosimilar Serve As Non-Medical Switching Case Study?
How US Can Learn From Biosimilar Implementation In EU
A New Year Filled With Debate Over Drug Pricing, PwC Predicts
Biosimilar User Fee Negotiations Won't Start Until 2016
FDA's Woodcock Expresses Concern Not All Generics Are Equivalent, But OGD May Have Solution


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts